Compare WES & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WES | WST |
|---|---|---|
| Founded | 2007 | 1923 |
| Country | United States | United States |
| Employees | N/A | 10600 |
| Industry | Natural Gas Distribution | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3B | 16.6B |
| IPO Year | 2008 | N/A |
| Metric | WES | WST |
|---|---|---|
| Price | $41.23 | $230.52 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $41.00 | ★ $338.00 |
| AVG Volume (30 Days) | ★ 1.3M | 1.0M |
| Earning Date | 02-18-2026 | 02-12-2026 |
| Dividend Yield | ★ 8.78% | 0.38% |
| EPS Growth | N/A | ★ 0.17 |
| EPS | 3.38 | ★ 6.75 |
| Revenue | ★ $3,740,425,000.00 | $3,017,900,000.00 |
| Revenue This Year | $8.43 | $6.97 |
| Revenue Next Year | $7.01 | $6.27 |
| P/E Ratio | ★ $12.26 | $34.23 |
| Revenue Growth | ★ 5.81 | 4.92 |
| 52 Week Low | $33.60 | $187.43 |
| 52 Week High | $43.11 | $347.85 |
| Indicator | WES | WST |
|---|---|---|
| Relative Strength Index (RSI) | 58.78 | 27.57 |
| Support Level | $40.27 | $232.06 |
| Resistance Level | $42.22 | $243.91 |
| Average True Range (ATR) | 0.94 | 9.07 |
| MACD | -0.02 | -3.59 |
| Stochastic Oscillator | 50.53 | 11.77 |
Western Midstream Partners LP is a USA-based company which own, operate, acquire and develop midstream energy assets. The company through its subsidiary is engaged in the business of gathering, processing, compressing, treating and transporting natural gas, condensate, NGLs and crude oil. It owns or has investments in assets located in the Rocky Mountains (Colorado, Utah, and Wyoming), the Mid-Continent (Kansas and Oklahoma), North-central Pennsylvania and Texas.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.